XML 41 R24.htm IDEA: XBRL DOCUMENT v3.25.3
Business Segment
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Business Segment Business segment
We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Our chief operating decision maker ("CODM") is the Chief Executive Officer, who decides how to allocate resources and assesses segment performance based on the net loss reported in the Condensed Consolidated Statements of Operations.
The table below is a summary of the segment net loss, including significant segment expenses (in millions):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Total revenues26 48 214 232 
Less:
Late-stage development programs (1)
78 69 207 196 
Early-stage development and preclinical programs (2)
33 34 113 92 
Compensation and personnel costs59 62 187 190 
Depreciation and amortization2 2 7 7 
Impairment of long-lived assets— — — 20 
Interest income, net(7)(13)(25)(38)
Income tax expense— — — — 
Other segment items (3)
24 23 71 68 
Partnership reimbursements(28)(37)(99)(114)
Segment and Consolidated net loss$(135)$(92)$(247)$(189)
(1) R&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once a molecule enters into one or more Phase 3 clinical trials.
(2) R&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.
(3) Other segment items includes non-allocated program costs and other G&A costs.
Total segment assets at September 30, 2025 and 2024 were $1.0 billion and $1.3 billion, respectively.